ENGN trades 264.6% below Wall Street's consensus target of $7.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ENGN achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of July 8, 2026, enGene Holdings Inc. (ENGN) has a Wall Street consensus price target of $7.00, based on estimates from 9 covering analysts. With the stock currently trading at $1.92, this represents a potential upside of +264.6%. The company has a market capitalization of $98M.
Analyst price targets range from a low of $2.00 to a high of $28.00, representing a 371% spread in expectations. The median target of $3.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Hold, with 4 analysts rating the stock as a Buy or Strong Buy,5 rating it Hold, and 0 rating it Sell or Strong Sell. The mixed ratings reflect uncertainty about near-term direction.
From a valuation perspective, ENGN trades at a trailing P/E of -0.8x. Analysts expect EPS to grow -106.6% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
RCKTRocket Pharmaceuticals, Inc. | $444M | $4.07 | $5.00 | +22.9% | Buy | — | 19 |
KRYSKrystal Biotech, Inc. | $10.9B | $368.60 | $336.40 | -8.7% | Buy | 48.0x | 17 |
TGTXTG Therapeutics, Inc. | $8.2B | $53.52 | $64.00 | +19.6% | Buy | 39.4x | 13 |
JANXJanux Therapeutics, Inc. | $985M | $16.15 | $23.83 | +47.6% | Buy | — | 15 |
FATEFate Therapeutics, Inc. | $352M | $3.02 | $5.50 | +82.1% | Buy | — | 31 |
NTLAIntellia Therapeutics, Inc. | $2.0B | $17.43 | $26.13 | +49.9% | Buy | — | 39 |
EDITEditas Medicine, Inc. | $367M | $3.75 | $5.00 | +33.3% | Buy | — | 25 |
CRSPCRISPR Therapeutics AG | $5.9B | $60.77 | $71.67 | +17.9% | Buy | — | 38 |
BEAMBeam Therapeutics Inc. | $3.9B | $37.92 | $48.00 | +26.6% | Buy | — | 27 |
ILMNIllumina, Inc. | $29.1B | $191.76 | $156.27 | -18.5% | Buy | 36.6x | 50 |
Quick answers to the most common questions about buying ENGN stock.
The consensus Wall Street price target for ENGN is $7, representing 264.6% upside from the current price of $1.92. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ENGN has a consensus rating of "Hold" based on 9 Wall Street analysts. The rating breakdown is mixed, with 5 Hold ratings making up the largest segment. The consensus 12-month price target of $7 implies 264.6% upside from current levels.
ENGN's current price is $1.92 with a consensus target of $7 (264.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $28 for ENGN, while the most conservative target is $2. The consensus of $7 represents the median expectation. These targets typically reflect 12-month expectations.
ENGN is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 4 have Buy ratings, 5 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ENGN stock forecast based on 9 Wall Street analysts shows a consensus price target of $7, with estimates ranging from $2 (bear case) to $28 (bull case). The median consensus rating is "Hold".
Wall Street analysts are very optimistic on ENGN, with a "Hold" consensus rating and $7 price target (264.6% upside). 4 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ENGN analyst price targets range from $2 to $28, a 371% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $7 consensus represents the middle ground.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.